

company announcement

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 6 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen
2 Reason for the notification		
a)	Position/status	President and CEO
b)	Initial notification/Amendment	Initial notification
3 Details of the issuer		
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4 Details of the transaction(s)		

a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 818.66</td> <td>35 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 818.66	35 shares		
Price(s)	Volume(s)							
DKK 818.66	35 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	35 shares DKK 818.66						
e)	Date of the transaction	2024-02-05						
f)	Place of the transaction	(AQEA) AQUIS EXCHANGE EUROPE AUCTION ON DEMAND (AOD)						

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen
2	Reason for the notification	
a)	Position/status	President and CEO
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares

c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 801.37</td> <td>309 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 801.37	309 shares		
Price(s)	Volume(s)							
DKK 801.37	309 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	309 shares DKK 801.37						
e)	Date of the transaction	2024-02-05						
f)	Place of the transaction	(AQEU) AQUIS EXCHANGE EUROPE						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 808.08</td> <td>8,510 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 808.08	8,510 shares		
Price(s)	Volume(s)							
DKK 808.08	8,510 shares							

d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	8,510 shares DKK 808.08
e)	Date of the transaction	2024-02-05
f)	Place of the transaction	(BEUP) CBOE EUROPE - DXE PERIODIC (NL)

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 805.90</td> <td>355 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 805.90	355 shares		
Price(s)	Volume(s)							
DKK 805.90	355 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	355 shares DKK 805.90						
e)	Date of the transaction	2024-02-05						

f)	Place of the transaction	(CEUD) CBOE EUROPE - DXE DARK ORDER BOOK (NL)
----	--------------------------	---

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 811.02</td> <td>35,585 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 811.02	35,585 shares		
Price(s)	Volume(s)							
DKK 811.02	35,585 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	35,585 shares DKK 811.02						
e)	Date of the transaction	2024-02-05						
f)	Place of the transaction	(CEUX) CBOE EUROPE - DXE ORDER BOOKS (NL)						

1 Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person Lars Fruergaard Jørgensen						
2 Reason for the notification							
a)	Position/status President and CEO						
b)	Initial notification/Amendment Initial notification						
3 Details of the issuer							
a)	Name Novo Nordisk A/S						
b)	LEI 549300DAQ1CVT6CXN342						
4 Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction Sale of shares						
c)	Price(s) and volume(s) <table border="1" data-bbox="865 1106 1362 1258"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 810.89</td> <td>3,962 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 810.89	3,962 shares		
Price(s)	Volume(s)						
DKK 810.89	3,962 shares						
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 3,962 shares DKK 810.89						
e)	Date of the transaction 2024-02-05						
f)	Place of the transaction (MCSE) NASDAQ COPENHAGEN A/S - AUCTION ON DEMAND						

1 Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person Lars Fruergaard Jørgensen

2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 818.83</td> <td>159 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 818.83	159 shares		
Price(s)	Volume(s)							
DKK 818.83	159 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	159 shares DKK 818.83						
e)	Date of the transaction	2024-02-05						
f)	Place of the transaction	(SGMV) SIGMA X EUROPE AUCTION BOOK						

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen
2	Reason for the notification	
a)	Position/status	President and CEO
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	

a)	Name	Novo Nordisk A/S							
b)	LEI	549300DAQ1CVT6CXN342							
4	Details of the transaction(s)								
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333							
b)	Nature of the transaction	Sale of shares							
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 820.50</td> <td>26 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>		Price(s)	Volume(s)	DKK 820.50	26 shares		
Price(s)	Volume(s)								
DKK 820.50	26 shares								
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	26 shares DKK 820.50							
e)	Date of the transaction	2024-02-05							
f)	Place of the transaction	(TQEA) TURQUOISE EUROPE - LIT AUCTIONS							

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen	
2	Reason for the notification		
a)	Position/status	President and CEO	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		

a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 808.69</td> <td>574 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 808.69	574 shares		
Price(s)	Volume(s)							
DKK 808.69	574 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	574 shares DKK 808.69						
e)	Date of the transaction	2024-02-05						
f)	Place of the transaction	(TQEX) TURQUOISE EUROPE						

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen
2	Reason for the notification	
a)	Position/status	President and CEO
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares

c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 809.76</td> <td>129,916 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 809.76	129,916 shares		
Price(s)	Volume(s)							
DKK 809.76	129,916 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	129,916 shares DKK 809.76						
e)	Date of the transaction	2024-02-05						
f)	Place of the transaction	(XCSE) NASDAQ COPENHAGEN A/S						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 807.51</td> <td>569 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 807.51	569 shares		
Price(s)	Volume(s)							
DKK 807.51	569 shares							

d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	569 shares DKK 807.51
e)	Date of the transaction	2024-02-05
f)	Place of the transaction	(XPAC) POSIT AUCTION

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Amendment to company announcement no. 8 / 2024 which erroneously stated 10,000 shares too many, cf. also Remuneration Report 2023, page 20						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>139,422 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	139,422 shares		
Price(s)	Volume(s)							
DKK 0.00	139,422 shares							

d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	139,422 shares DKK 0.00
e)	Date of the transaction	2024-01-31
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 797.80</td> <td>16,000 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 797.80	16,000 shares		
Price(s)	Volume(s)							
DKK 797.80	16,000 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	16,000 shares DKK 797.80						
e)	Date of the transaction	2024-02-05						
f)	Place of the transaction	NASDAQ COPENHAGEN A/S						

1		Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Tania Sabroe							
2		Reason for the notification							
a)	Position/status	Executive Vice President							
b)	Initial notification/Amendment	Initial notification							
3		Details of the issuer							
a)	Name	Novo Nordisk A/S							
b)	LEI	549300DAQ1CVT6CXN342							
4		Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333							
b)	Nature of the transaction	Sale of shares							
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 797.10</td> <td>21,264 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>		Price(s)	Volume(s)	DKK 797.10	21,264 shares		
Price(s)	Volume(s)								
DKK 797.10	21,264 shares								
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	21,264 shares DKK 797.10							
e)	Date of the transaction	2024-02-05							
f)	Place of the transaction	NASDAQ COPENHAGEN A/S							

1		Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Marcus Schindler	

2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 809.71</td> <td>36,392 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 809.71	36,392 shares		
Price(s)	Volume(s)							
DKK 809.71	36,392 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	36,392 shares DKK 809.71						
e)	Date of the transaction	2024-02-06						
f)	Place of the transaction	NASDAQ COPENHAGEN A/S						

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Camilla Sylvest
2	Reason for the notification	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	

a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 809.64</td> <td>74,915 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 809.64	74,915 shares		
Price(s)	Volume(s)							
DKK 809.64	74,915 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	74,915 shares DKK 809.64						
e)	Date of the transaction	2024-02-05						
f)	Place of the transaction	NASDAQ COPENHAGEN A/S						

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Henrik Ehlers Wulff
2	Reason for the notification	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	

a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 823.09</td> <td>60,000 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 823.09	60,000 shares		
Price(s)	Volume(s)							
DKK 823.09	60,000 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	60,000 shares DKK 823.09						
e)	Date of the transaction	2024-02-06						
f)	Place of the transaction	NASDAQ COPENHAGEN A/S						

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

Contacts for further information

Media:

Ambre James-Brown

+45 3079 9289

abmo@novonordisk.com

Elizabeth DeLuca (US)

+1 609 580 9868

edel@novonordisk.com

Investors:

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Frederik Taylor Pitter

+45 3075 8259

fptr@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Mark Joseph Root (US)

+1 848 213 3219

mjhr@novonordisk.com

Sina Meyer

+45 3079 6656

azey@novonordisk.com